Interakcje fluorochinolonow z jonami metali i ich znaczenie kliniczne

• Autorzy: Jakubowski P , Jaroszewski J.J.

Warianty tytułu

EN

Interactions of fluoroquinolones with ions of metals and their clinical significance

• Języki publikacji: PL

Abstrakty

EN

Fluoroquinolones are a group of antimicrobial agents which are widely used in human and veterinary medicine. These drugs may cause interactions with other compounds. The paper describes the latest views concerning interactions between fluoroquinolones and metal cations. Simultaneous administration of fluoroquinolones with 2- and 3-valent cations causes a significant decrease in the bioavailability of these drugs due to the effect of chelating cations by carboxylate and the carbonyl group of fluoroquinolone. These interactions may result in an inefficient antimicrobial therapy and, in order to prevent this occurring, spaced dosing of fluoroquinolones and a formulation containing metal cations is recommended.

Słowa kluczowe

PL

fluorochinolony; interakcje; kationy; znaczenie kliniczne; jony metali

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2006
• Tom: 62
• Numer: 10
• Strony: 1120-1122
• Opis fizyczny: s.1120-1122,rys.,bibliogr.

Twórcy

autor

Jakubowski P

• Uniwersytet Warminsko-Mazurski, ul.Oczapowskiego 13, 10-718 Olsztyn

autor

Jaroszewski J.J.

Bibliografia

• 1.Bertone J., Horspool L.: Equine Clinical Pharmacology. Elsevier, Hardbound 2004, s. 40.
• 2.Chu D., Fernandes P.: Structure-activity relationships of the fluoroquinolones. Antimicrob. Agents Chemother. 1989, 33, 131-135.
• 3.Deitz W., Bailey J., Froelich E.: In vitro antibacterial properties of nalidixic acic, a new drug active against gram-negative organisms. Antimicrob. Agents Chemother. 1963, 161, 583-587.
• 4.Deppermann K., Lode H.: Fluoroquinolones: Interaction profile during enteral absorption. Drugs 1993, 45, 65-72.
• 5.Hoffken G., Borner K., Glatzel P., Koeppe P., Lode H.: Reduced internal absorption of ciprofloxacin in the presence of antacids. Eur. J. Clin. Microbiol 1985, 4, 345.
• 6.Ihrke P., Papich M., Demanuelle T.: The use of fluoroquinolones in veterinary dermatology. Vet. Dermatol. 1999, 10, 193-204.
• 7.Jaehde U., Sorgel F., Stephan U., Schunack W.: Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob. Agents Chemother. 1994, 38, 1129-1133.
• 8.Linder B., Wiese A., Brandenburg K., Seydel U., Dalhoff A.: Lack of interaction of fluoroquinolones with lipopolysaccharides. Antimicrob. Agents Chemother. 2002, 46, 1568-1570.
• 9.Lomaestro B., Bailie G.: Absorption interactions with FQ. 1995 update. Drug Saf. 1995, 12, 314-333.
• 10.Papaioannou D., Katsoulos P., Panousis N., Karatzias H.: The role of natural and synthetic zeolites as feed additives on the prevention and/or the treatment of certain farm animal diseases: A review. Microporous Mesosporous Mater. 2005, 84, 161-170.
• 11.Quain R., Barton T., Fishman N., Weiner M., Lautenbach E.: Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance. Int. J. Antimicrob. Agents 2005, 26, 327- -330.
• 12.Stahlmann R.: Clinical toxicological aspects of fluoroquinolones. Toxicol. Lett. 2002, 127, 269-277.
• 13.Suda K., Garey K., Danziger L.: Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm. World Sci. 2005, 27, 81-82.
• 14.Turel I: The interactions of metal ions with quinolone antibacterial agents. Coord. Chem. Rev. 2002, 232, 27-47.
• 15.Turel I., Bukovec N.: Complex formation between some metals and a quinolone family member (ciprofloxacin). Polyhedron 1995, 15, 269-275.
• 16.Van Bambeke F., Michot J., Van Eldere J., Tulkens P.: Quinolones in 2005: an update. Cin. Microbiol. Infect. 2005, 11, 256-280.
• 17.Wallis S., Charles B., Gahan L., Filippich L., Bredhauer M., Duckworth P.: Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetics studies in the dog. J. Pharm. Sci. 1996, 85, 803-809.
• 18.Wigley D.: Structure and mechanism of DNA topoisomerases. Annu. Rev. Biophys. Struct. 1995, 24, 185-208.